Schematic of complement activation, highlighting potential therapeutic targets under study. Complement inhibitors are summarized according to their target and the step of the complement pathway involved. Eculizumab, ravulizumab, crovalimab, tesidolumab, mubodina, coversin, zilucoplan, cemdisiran, zimura, ABP959, and REGN3918 inhibit C5; pegcetacoplan and AMY-101 inhibit C3 and C3 convertase activity; mini-FH/AMY-201 inhibits alternative pathway C3 convertase; iptacopan and IONIS-FB-LRx inhibit factor B; danicopan, lampalizumab, BCX9930, and ACH-5528 inhibit factor D; CLG561, pegcetacoplan, and AMY-101 inhibit properdin (P); sutimlimab inhibits C1s of the classical pathway; narsoplimab inhibits MASP-2 of the lectin pathway; mirococept inhibits C3 and C5 convertases; and avacopan inhibits C5a receptor and IFX-1 C5a. Professional illustration by Somersault 18:24.